To explore this hypothesis, scalar amounts of exogenous AAT were added to the samples, somehow mimicking the current “augmentation” therapy in use for the treatment of patients affected by the genetic disease known as AAT deficiency [23,24]. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.